Adaptimmune Therapeutics PLC (ADAP)
0.8125
+0.01
(+1.59%)
USD |
NASDAQ |
Nov 04, 13:10
Adaptimmune Therapeutics Debt to Equity Ratio: 0.2592 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
June 30, 2024 | 0.2592 |
March 31, 2024 | 0.00 |
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 0.00 |
September 30, 2022 | 0.00 |
June 30, 2022 | 0.00 |
March 31, 2022 | 0.00 |
December 31, 2021 | 0.00 |
September 30, 2021 | 0.00 |
June 30, 2021 | 0.00 |
March 31, 2021 | 0.00 |
December 31, 2020 | 0.00 |
September 30, 2020 | 0.00 |
June 30, 2020 | 0.00 |
March 31, 2020 | 0.00 |
Date | Value |
---|---|
December 31, 2019 | 0.00 |
September 30, 2019 | 0.00 |
June 30, 2019 | 0.00 |
March 31, 2019 | 0.00 |
December 31, 2018 | 0.00 |
September 30, 2018 | 0.00 |
June 30, 2018 | 0.00 |
March 31, 2018 | 0.00 |
December 31, 2017 | 0.00 |
September 30, 2017 | 0.00 |
June 30, 2017 | 0.00 |
March 31, 2017 | 0.00 |
December 31, 2016 | 0.00 |
September 30, 2016 | 0.00 |
June 30, 2016 | 0.00 |
March 31, 2016 | 0.00 |
September 30, 2015 | 0.00 |
December 31, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
0.2592
Maximum
Jun 2024
0.0136
Average
--
Median
Dec 2019
Debt to Equity Ratio Benchmarks
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 321.70M |
Total Liabilities (Quarterly) | 225.43M |
Shareholders Equity (Quarterly) | 96.27M |
Current Ratio | 3.092 |
Net Debt Paydown Yield | -2.00% |